Bipolar disorder and complementary medicine: Current evidence, safety issues, and clinical considerations

Journal of Alternative and Complementary Medicine

Volumn 17, Issue 10, 2011, Pages 881-890

  Sarris, Jerome ^a,b   Lake, James ^c   Hoenders, Rogier ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c Arizona Center for Integrative Medicine   (United States)

^d Lentis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BRANCHED CHAIN AMINO ACID; CARBAMAZEPINE; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; HALOPERIDOL; HERBACEOUS AGENT; HYPNOTIC SEDATIVE AGENT; ICOSAPENTAENOIC ACID; INOSITOL; LITHIUM; MAGNESIUM; MAGNESIUM OXIDE; MAGNESIUM SULFATE; MINERAL; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; VALPROIC ACID; VITAMIN;

ACUPUNCTURE; ALTERNATIVE MEDICINE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); DATA BASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; HYPOMANIA; INTEGRATIVE MEDICINE; MAJOR DEPRESSION; MANIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREMOR;

ACETYLCYSTEINE; ACUPUNCTURE THERAPY; AMINO ACIDS, BRANCHED-CHAIN; BIPOLAR DISORDER; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; HUMANS; INTEGRATIVE MEDICINE; MAGNESIUM; MICRONUTRIENTS; PSYCHOTROPIC DRUGS; TRYPTOPHAN;

EID: 80054865721     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2010.0481     Document Type: Review

References (86)

1. Sarris J, Wardle J, eds. Clinical Naturopathy: An Evidence-Based Guide to Practice. Sydney: Elsevier, 2010.
2. Knaudt P, Connor K, Weisler R. Alternative therapy use bypsychiatric outpatients. J Nerv Ment Dis 1999;187:692-695.
3. Hoenders H, Appelo M, Milders C. CAM and psychiatry:Opinions of patients and psychiatrists. Tijdschr Psychiatr2006;48:733-737.
4. Keaton D, Lamkin N, Cassidy KA, et al. Utilization of herbaland nutritional compounds among older adults with bipolardisorder and with major depression. Int J Geriatr Psychiatry2009;24:1087-1093.
5. Kessler RC, Soukup J, Davis RB, et al. The use of complementaryand alternative therapies to treat anxiety and depressionin the United States. Am J Psychiatry 2001;158:289-294. (Pubitemid 32116527)
6. Wu P, Fuller C, Liu X, et al. Use of complementary andalternative medicine among women with depression: Resultsof a national survey. Psychiatr Serv 2007;58:349-356. (Pubitemid 46480051)
7. Sirois FM. Motivations for consulting complementary andalternative medicine practitioners: A comparison of consumersfrom 1997-8 and 2005. BMC Complement AlternMed 2008;8:16.
8. Cooley K, Szczurko O, Perri D, et al. Naturopathic care foranxiety: A randomized controlled trial ISRCTN78958974.PLoS One 2009;4:e6628.
9. Andreescu C, Mulsant BH, Emanuel JE. Complementaryand alternative medicine in the treatment of bipolar disorder:A review of the evidence. J Affect Disord 2008;110:16-26.
10. Sarris J, Kavanagh D, Byrne G. Adjuvant use of nutritionaland herbal medicines with antidepressants, mood stabilizersand benzodiazepines. J Psychiatr Res 2010;44:32-41.
11. Cohen J. Statistical Power Analyses for the Behavioral Sciences,vol 2. Hillsdale, NJ: Lawrence Erlbaum Associates,1988.
12. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the NationalComorbidity Survey replication. Arch Gen Psychiatry2007;64:543-552. (Pubitemid 46718287)
13. Gurling H, Smyth C, Kalsi G, et al. Linkage findings in bipolardisorder. Nat Genet 1995;10:8-9.
14. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidencefor mitochondrial dysfunction in bipolar disorder.Arch Gen Psychiatry 2004;61:300-308. (Pubitemid 38295832)
15. Miklowitz DJ, Johnson SL. The psychopathology and treatmentof bipolar disorder. Annu Rev Clin Psychol 2006;2:199-235.
16. American Psychiatric Association. Diagnostic and StatisticalManual of Mental Disorders, 4th text revision ed. Arlington,VA: American Psychiatric Association, 2000.
17. Benazzi F. Is there a continuity between bipolar and depressivedisorders? Psychother Psychosom 2007;76:70-76.
18. Cassano GB, Frank E, Miniati M, et al. Conceptual underpinningsand empirical support for the mood spectrum.Psychiatr Clin North Am 2002;25:699-712, v. (Pubitemid 35351202)
19. Suppes T, Kelly DI, Perla JM. Challenges in the managementof bipolar depression. J Clin Psychiatry 2005;66(suppl 5):11-16.
20. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term naturalhistory of the weekly symptomatic status of bipolar Idisorder. Arch Gen Psychiatry 2002;59:530-537. (Pubitemid 34602935)
21. Pompili M, Serafini G, Del Casale A, et al. Improving adherencein mood disorders: The struggle against relapse,recurrence and suicide risk. Expert Rev Neurother 2009;9:985-1004.
22. Cousins DA, Young AH. The armamentarium of treatmentsfor bipolar disorder: A review of the literature. Int J Neuropsychopharmacol2007;10:411-431. (Pubitemid 46701010)
23. Culver JL, Arnow BA, Ketter TA. Bipolar disorder: Improvingdiagnosis and optimizing integrated care. J ClinPsychol 2007;63:73-92. (Pubitemid 46150926)
24. Fleck DE, Keck PE Jr, Corey KB, Strakowski SM. Factorsassociated with medication adherence in African Americanand white patients with bipolar disorder. J Clin Psychiatry2005;66:646-652. (Pubitemid 40733710)
25. Perlick DA, Rosenheck RA, Clarkin JF, et al. Symptomspredicting inpatient service use among patients with bipolaraffective disorder. Psychiatr Serv 1999;50:806-812. (Pubitemid 29258957)
26. Benjamin AB. A unique consideration regarding medicationcompliance for bipolar affective disorder: Exercise performance.Bipolar Disord 2007;9:928-929. (Pubitemid 350215121)
27. Miklowitz DJ, Scott J. Psychosocial treatments for bipolardisorder: Cost-effectiveness, mediating mechanisms, andfuture directions. Bipolar Disord 2009;11(suppl 2):110-122.
28. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders.Nutr J 2008;7:2.
29. Castle D, White C, Chamberlain J, et al. Group-based psychosocialintervention for bipolar disorder: Randomisedcontrolled trial. Br J Psychiatry 2010;196:383-388.
30. Hoenders H, Appelo M, Van den Brink H, et al. Protocol forCAM: Working on the judicious use within conventionalmental health care. Tijdschrift voor Psychiatrie 2010;52:343-348.
31. Nivoli AM, Colom F, Murru A, et al. New treatmentguidelines for acute bipolar depression: A systematic review.J Affect Disord 2011;129:14-26.
32. Kumar P, Clark M, eds. Clinical Medicine, 5th ed. London:W. B. Saunders, 2002.
33. Swann AC. The strong relationship between bipolar andsubstance-use disorder. Ann N Y Acad Sci 2010;1187:276-293.
34. Sarris J, Kavanagh D, Byrne G, et al. The Kava AnxietyDepression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract ofPiper methysticum. Psychopharmacology (Berl) 2009;205:399-407.
35. Sarris J, Schoendorfer N, Kavanagh D. Major depressivedisorder and nutritional medicine: A review of monotherapiesand adjuvant treatments. Nutr Rev 2009;67:125-131.
36. Sarris J. Herbal medicines in the treatment of psychiatricdisorders: A systematic review. Phytother Res 2007;21:703-716. (Pubitemid 47217768)
37. Wang H, Qi H, Wang B, et al. Is acupuncture beneficial indepression: A meta-analysis of 8 randomized controlledtrials? J Affect Disord 2008;111(2-3):125-134.
38. Barbour KA, Edenfield TM, Blumenthal JA. Exercise as atreatment for depression and other psychiatric disorders: Areview. J Cardiopulm Rehabil Prev 2007;27:359-367.
39. Jacka FN, Pasco JA, Mykletun A, et al. Association of Westernand traditional diets with depression and anxiety inwomen. Am J Psychiatry 2010;167:305-311.
40. Cuijpers P, van Straten A, Warmerdam L, Andersson G.Psychological treatment of depression: A meta-analytic databaseof randomized studies. BMC Psychiatry 2008;8:36.
41. Moses EL, Mallinger AG. St. John's Wort: Three cases ofpossible mania induction. J Clin Psychopharmacol 2000;20:115-117. (Pubitemid 30056371)
42. Boerth JM, Caley CF. Possible case of mania associated withma-huang. Pharmacotherapy 2003;23:380-383. (Pubitemid 36259343)
43. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine indepression: A comprehensive review of the literature. CurrPsychiatry Rep 2003;5:460-466. (Pubitemid 38899242)
44. Sarris J, Kavanagh DJ, Deed G, Bone KM. St. John's wort andkava in treating major depressive disorder with comorbidanxiety: A randomised double-blind placebo-controlled pilottrial. Hum Psychopharmacol 2009;24:41-48.
45. Whitten D, Myers D, Hawrelak J, Wohlmuth H. The effect ofSt John's wort extracts on CYP3A: A systematic review ofprospective clinical trials. Br J Clin Pharmacol 2006;62:512-526. (Pubitemid 44571572)
46. Waring WS. Management of lithium toxicity. Toxicol Rev2006;25:221-230.
47. Hibbeln JR. Fish consumption and major depression. Lancet1998;351:1213.
48. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fattyacids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-412. (Pubitemid 29215428)
49. Hamilton M. A rating scale for depression. J Neurol NeurosurgPsychiatry 1960;23:56-62.
50. Osher Y, Bersudsky Y, Belmaker R. Omega-3 eicosapentaenoicacid in bipolar depression: Report of a small open-labelstudy. J Clin Psychiatry 2005;66:726-729. (Pubitemid 40942418)
51. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoicacid in bipolar depression: Randomised doubleblindplacebo-controlled study. Br J Psychiatry 2006;188:46-50. (Pubitemid 43021926)
52. Young R, Biggs J, Ziegler V, Meyer D. A rating scale formania: Reliability, validity and sensitivity. Br J Psychiatry1978;133:429-435. (Pubitemid 9006756)
53. Frangou S, Lewis M, Wollard J, Simmons A. Preliminary invivo evidence of increased N-acetyl-aspartate following eicosapentanoicacid treatment in patients with bipolar disorder.J Psychopharmacol 2007;21:435-439. (Pubitemid 47077299)
54. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acidtreatment and T(2) whole brain relaxation times in bipolardisorder. Am J Psychiatry 2004;161:1922-1924. (Pubitemid 39314692)
55. Keck PE Jr, Mintz J, McElroy SL, et al. Double-blind, randomized,placebo-controlled trials of ethyl-eicosapentanoatein the treatment of bipolar depression and rapid cyclingbipolar disorder. Biol Psychiatry 2006;60:1020-1022. (Pubitemid 44739928)
56. Chiu CC, Huang SY, Chen CC, Su KP. Omega-3 fatty acidsare more beneficial in the depressive phase than in the manicphase in patients with bipolar I disorder. J Clin Psychiatry2005;66:1613-1614.
57. Clayton EH, Hanstock TL, Hirneth SJ, et al. Reduced maniaand depression in juvenile bipolar disorder associated withlong-chain omega-3 polyunsaturated fatty acid supplementation.Eur J Clin Nutr 2009;63:1037-1040.
58. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acidmonotherapy for pediatric bipolar disorder: A prospectiveopen-label trial. Eur Neuropsychopharmacol 2007;17:440-447. (Pubitemid 46497662)
59. Kaplan B, Crawford S, Field C, Simpson J. Vitamins, minerals,and mood. Psychol Bull 2007;133:747-760.
60. Scarna A, Gijsman HJ, McTavish SF, et al. Effects of abranched-chain amino acid drink in mania. Br J Psychiatry2003;182:210-213. (Pubitemid 36286733)
61. Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine forantioxidant therapy: Pharmacology and clinical utility. ExpertOpin Biol Ther 2008;8:1955-1962.
62. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine fordepressive symptoms in bipolar disorder: A double-blindrandomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475.
63. Montgomery SA, Asberg M. A new depression scale designedto be sensitive to change. Br J Psychiatry 1979;134:382-389. (Pubitemid 9136500)
64. Bell CJ, Hood SD, Nutt DJ. Acute tryptophan depletion: PartII. Clinical effects and implications. Aust N Z J Psychiatry2005;39:565-574. (Pubitemid 41613445)
65. Chouinard G, Young SN, Annable L. A controlled clinicaltrial of L-tryptophan in acute mania. Biol Psychiatry 1985;20:546-557. (Pubitemid 16033752)
66. Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot studyof magnesium aspartate hydrochloride (Magnesiocard) as amood stabilizer for rapid cycling bipolar affective disorderpatients. Prog Neuropsychopharmacol Biol Psychiatry1990;14:171-180. (Pubitemid 20078459)
67. Heiden A, Frey R, Presslich O, et al. Treatment of severemania with intravenous magnesium sulphate as a supplementarytherapy. Psychiatry Res 1999;89:239-246. (Pubitemid 30053006)
68. Giannini AJ, Nakoneczie AM, Melemis SM, et al. Magnesiumoxide augmentation of verapamil maintenance therapyin mania. Psychiatry Res 2000;93:83-87. (Pubitemid 30123138)
69. Chengappa K, Levine J, Gershon S, et al. Inositol as an addontreatment for bipolar depression. Bipolar Disord 2000;2:47-55.
70. Evins A, Demopulos C, Yovel I, et al. Inositol augmentationof lithium or valproate for bipolar depression. Bipolar Disord2006;8:168-174. (Pubitemid 44026769)
71. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithiumprophylaxis. J Affect Disord 1986;10:9-13.
72. Kaplan B, Simpson J, Ferre R, et al. Effective mood stabilizationwith a chelated mineral supplement: An open-labeltrial in bipolar disorder. J Clin Psychiatry 2001;62:936-944. (Pubitemid 34007958)
73. Simmons M. Nutritional approach to bipolar disorder. J ClinPsychiatry 2003;64:338; author reply 338-339.
74. Popper CW. Do vitamins or minerals (apart from lithium)have mood-stabilizing effects? J Clin Psychiatry 2001;62:933-935. (Pubitemid 34007957)
75. Kaplan BJ, Simpson JS, Ferre RC, et al. Effective mood stabilizationwith a chelated mineral supplement: An open-labeltrial in bipolar disorder. J Clin Psychiatry 2001;62:936-944. (Pubitemid 34007958)
76. Leiva DB. The neurochemistry of mania: A hypothesis ofetiology and rationale for treatment. Prog NeuropsychopharmacolBiol Psychiatry 1990;14:423-429.
77. Stoll AL, Sachs GS, Cohen BM, et al. Choline in the treatmentof rapid-cycling bipolar disorder: Clinical and neurochemicalfindings in lithium-treated patients. Biol Psychiatry1996;40:382-388. (Pubitemid 26301069)
78. Fierro A. Natural low dose lithium supplementation in manicdepressivedisease. Nutrition Perspectives, January 1988:10-11.
79. Tripuraneni B. Clinical psychiatry news. 143rd AnnualMeeting of the American Psychiatric Association. New York,May 14, 1990;18.
80. Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbalmedicine with carbamazepine for bipolar disorders: Adouble-blind, randomized, placebo-controlled study. J PsychiatrRes 2007;41:360-369.
81. Bacher NM, Lewis HA. Lithium plus reserpine in refractorymanic patients. Am J Psychiatry 1979;136:811-814. (Pubitemid 9206096)
82. Berlant JL. Neuroleptics and reserpine in refractory psychoses.J Clin Psychopharmacol 1986;6:180-184. (Pubitemid 16021624)
83. Sarris J, Kavanagh DJ. Kava and St John's wort: Currentevidence for use in mood and anxiety disorders. J AlternComplement Med 2009;15:827-836.
84. Fahmi M, Huang C, Schweitzer I. A case of mania inducedby hypericum. World J Biol Psychiatry 2002;3:58-59.
85. Izzo AA. Drug interactions with St. John's Wort (Hypericumperforatum): A review of the clinical evidence. Int J ClinPharmacol Ther 2004;42:139-148. (Pubitemid 38647590)
86. Dennehy EB, Schnyer R, Bernstein IH, et al. The safety, acceptability,and effectiveness of acupuncture as an adjunctivetreatment for acute symptoms in bipolar disorder. J ClinPsychiatry 2009;70:897-905.